Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

34,100

Employees34,100

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

34,100

Employees34,100

BMY Key Statistics

Market cap

96.98B

Market cap96.98B

Price-Earnings ratio

19.06

Price-Earnings ratio19.06

Dividend yield

5.21%

Dividend yield5.21%

Average volume

9.40M

Average volume9.40M

High today

$47.44

High today$47.44

Low today

$46.78

Low today$46.78

Open price

$47.02

Open price$47.02

Volume

4.67M

Volume4.67M

52 Week high

$63.33

52 Week high$63.33

52 Week low

$42.96

52 Week low$42.96

BMY News

Simply Wall St 1d

Evaluating Bristol-Myers Squibb’s Valuation After Real-World Camzyos Study Results at European Cardiology Congress

Advertisement Most Popular Narrative: 28.1% Undervalued Bristol-Myers Squibb (BMY) just made waves at the European Society of Cardiology Congress, unveiling n...

TipRanks 1d

Cautious Optimism for Bristol-Myers Squibb Amid Promising Data and Ongoing Concerns

William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating on September 5. Elevate Your Investing Strategy: Take a...

TipRanks 2d

Hold Recommendation for Bristol-Myers Squibb Due to Cobenfy’s Modest Growth and Revenue Projections

Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb, retaining the price target of $47.00. Elevate Your Investing Strategy: T...

Analyst ratings

72%

of 29 ratings

Buy

24.1%

Hold

72.4%

Sell

3.4%

More BMY News

TipRanks 2d

BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.